Summary We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About 75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean percent NK activity of healthy donors -2 SD) in patients with lymphocyte depletion histologic grade of the disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL comparable to that of healthy donors.
Hodgkin's Disease (HD) is a malignant lymphoma which is frequently associated with defective cell mediated immunity (CMI) and T cell hyporesponsiveness, even at the early stages and in prognostically better grades of the disease (Aghai, 1986; Romagnani et al., 1985) . The possible mechanisms of impairment of CMI associated with active HD include an intrinsic defect of T cells, serum inhibitory factors and activation of suppressor monocytes or lymphocytes. We have investigated most of these aspects of T cell deficiencies and their regulation (Gulwani et al., 1986; Karande et al., 1982; Moghe et al., 1980 Moghe et al., , 1981 Mukhopadhyaya et al., 1983 Mukhopadhyaya et al., , 1987a and also the Interleukin-2 (IL-2) mediated events in HD (Damle et al., 1990; Gangal et al., 1987; Joshi et al., 1987; Mukhopadhyaya et al., 1987b) .
Amongst the known cellular effector mechanisms, natural killer (NK) cell activity mediated by large granular lymphocytes, is thought to represent the first line of defence against cancer and viral infections (Lotzova, 1985) . Low NK cell activity has frequently been reported in active HD (Berenyi et al., 1986; Frydecka, 1985; Hawrylowicz et al., 1982; Levy et al., 1984; Komiyama et al., 1987; Tursz et al., 1982) . The cytotoxic activity of lymphokine activated killer (LAK) cells, a promising candidate for adoptive immunotherapy of metastatic cancers, has been studied in various solid tumours and in some haematological malignancies like leukemia and nonHodgkin's lymphoma (NHL) (Dawson et al., 1986; Oshimi et al., 1986; Lotzova, 1987; Rajaram et al., 1990; Tatake et al., 1989) but not so far in HD.
We report here the NK and LAK cell activities of peripheral blood lymphocytes (PBL) from untreated HD patients classified according to various histopathological grades and clinical stages. The frequency of LAK cell precursors has also been studied using limiting dilution analysis (LDA Separation of lymphocytes PBL were separated on Ficoll-Hypaque (FH) gradient (Pharmacia, Sweden). The non-adherent PBL were obtained to assess NK activity as described before (Dabholkar et al., 1986) . LAK cells were generated from the total PBL population using the predetermined optimum dose of 10 u recombinant IL-2 (rIL-2, Biogen, S.A., Switzerland) per 1 x 106 lymphocytes (Tatake et al., 1989) .
Cytotoxicity assay and targets
The NK and LAK cell activities were determined using the standard four-hour 5"Chromium release assay (Dabholkar et al., 1986; Tatake et al., 1989) . The NK-sensitive targets used were K562 cells. The NK-resistant monolayer cell lines used as LAK targets were VIP (melanoma) and T-24 (bladder carcinoma).
The cytotoxicity assays were done at three effector: target (E:T) ratios of 50:1, 25:1 and 12.5:1. The results have been expressed as percent cytotoxicity at E:T = 50:1.
Limiting dilution analysis (LDA)
The frequency of LAK cell progenitors was determined using LDA as described earlier (Tatake et al., 1989) .
Results NK cell activity PBL of both healthy donors and HD patients showed a wide range of NK activity (Figure 1 ). The mean NK activity of the HD patients (mean ± S.E. = 42 ± 3.4) was comparable to that of healthy donors (45 ± 3). About 25% of the HD patients were low NK responders (cytotoxicity less than mean percent cytotoxicity of healthy donors -2 SD).
An analysis of the NK cell activity in patients with respect to various histopathological grades showed that the percentage of low NK responders was markedly more in the patients % Low NK responders with LD grade, which has a poor prognostic value ( Figure  2 ). There was also an increased percentage of low NK responders in patients with stage IV disease (Figure 2 ). Although the number of patients belonging to these categories was small, the data indicate the possibility of a prognostically useful correlation between NK cell response and disease progression.
LAK cell activity The PBL from HD patients had somewhat better, but not significantly higher, LAK cell activity against all three targets (K562, VIP and T-24 cells) than that of the healthy donors ( Figure 3 ). As indicated in the figure, even the low NK responder patients showed good LAK activity. The LAK cells from both groups showed 0-8% killing of allogeneic normal PHA transformed blasts used as control targets (data not shown).
Frequency distribution of LAK cell precursors We determined the frequency of LAK cell precursors in PBL of five healthy donors and five HD patients by LDA. Figure  4 illustrates the data transformed into fitting regression line plots.
The frequency of LAK cell progenitors in PBL of HD patients (mean reciprocal frequency ± S.E. = 1/686 1/ 3200) was comparable to that in healthy donors (1/428 1/ 2397) which is reflected in their LAK cell function as mentioned earlier (Figure 3 ).
Discussion
Extensive in vivo and in vitro studies conducted on patients with HD have shown abnormalities in immune functions in this disease, especially with T cell responses (Aghai, 1986; Romagnani et al., 1985) . Considering this, it is interesting to note that we showed efficient NK and LAK cell cytotoxic functions of PBL from untreated HD patients.
In (Berenyi et al., 1986; Frydecka, 1985; Hawrylowicz et al., 1982; Levy et al., 1984; Tursz et al., 1982; Komiyama et al., 1987) suggesting that the defect in the killing ability of NK cells in a child with HD could be due to a deficient release of NKCF. Normal NK activity has been demonstrated in HD patients in remission (Berenyi et al., 1986) .
In recent years, LAK cells have been considered an important cytotoxic effector mechanism, owing to the ubiquitous presence of LAK cell precursors, the ease with which LAK cells can be generated in vitro and their broad spectrum of lytic activity (Grimm, 1986; Rosenberg, 1988) . LAK cell therapy has been tried in solid tumours and in NHL (Rosenberg, 1988; Rosenberg et al., 1987) 
